MedTrace Logo

Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer

NCT03198923 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-09-25

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based immunotherapy in subjects with non small cell lung cancer.

Conditions

Interventions

BIOLOGICAL

natural killer and natural killer T cell

The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.

Sponsors & Collaborators

  • Shanghai Houchao Biotechnology Co., Ltd

    collaborator UNKNOWN

  • Wenxiang Wang

    lead OTHER

Principal Investigators

  • Wenxiang Wang, PhD · Hunan Province Tumor Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198923 on ClinicalTrials.gov